Metabolic Associated Fatty Liver Disease (MAFLD): Assessing the Knowledge and Practice of Primary Care Doctors in Seremban District, Negeri Sembilan

Overview

Journal Malays Fam Physician

Specialty Public Health

Date 2024 Sep 2

PMID 39220239

Authors

Kalaivaani Vijan

Athirah Ali

Nur Adhajirin Mohamed Idrus

Priscilla Lourdesamy

Shamini Margammuthu

Suguna Perumal

Cheong Lieng Teng

Imran Ahmad

Affiliations

Soon will be listed here.

Abstract

Introduction: Metabolic-associated fatty liver disease (MAFLD) is the liver manifestation of metabolic syndrome, which is commonly seen in primary care settings. This study aimed to determine the knowledge and practice of primary care physicians regarding MAFLD in Seremban District, Negeri Sembilan.

Methods: This cross-sectional study was conducted among medical officers in 14 health clinics in Seremban District, using a validated, self-administered online questionnaire.

Results: A total of 240 medical officers from 14 health clinics in Seremban District, participated in this study. Most participants (85.4%) passed the knowledge test. Their practice was acceptable, but only a minority were familiar with non-invasive testing of liver fibrosis (e.g. APRI or FIB-4), medication and specific diet for the treatment of MAFLD.

Conclusion: Most primary care physicians in Seremban District are knowledgeable in identifying risk factors and managing patients with MAFLD. However, there are still areas to improve in terms of management, particularly regarding the use of silymarin, vitamin E and pioglitazone.

References

Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L . Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008; 135(1):100-10. DOI: 10.1053/j.gastro.2008.03.078. View

Duseja A, Chalasani N . Epidemiology and risk factors of nonalcoholic fatty liver disease (NAFLD). Hepatol Int. 2015; 7 Suppl 2:755-64. DOI: 10.1007/s12072-013-9480-x. View

Younossi Z, Anstee Q, Marietti M, Hardy T, Henry L, Eslam M . Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2017; 15(1):11-20. DOI: 10.1038/nrgastro.2017.109. View

Li B, Zhang C, Zhan Y . Nonalcoholic Fatty Liver Disease Cirrhosis: A Review of Its Epidemiology, Risk Factors, Clinical Presentation, Diagnosis, Management, and Prognosis. Can J Gastroenterol Hepatol. 2018; 2018:2784537. PMC: 6051295. DOI: 10.1155/2018/2784537. View

Cohen-Schotanus J, van der Vleuten C . A standard setting method with the best performing students as point of reference: practical and affordable. Med Teach. 2010; 32(2):154-60. DOI: 10.3109/01421590903196979. View

Chan W, Tan S, Chan S, Lee Y, Tee H, Mahadeva S . Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease. J Gastroenterol Hepatol. 2022; 37(5):795-811. PMC: 9303255. DOI: 10.1111/jgh.15787. View

Mattos A, Debes J, Dhanasekaran R, Benhammou J, Arrese M, Patricio A . Hepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge. World J Hepatol. 2021; 13(9):1107-1121. PMC: 8473502. DOI: 10.4254/wjh.v13.i9.1107. View

Lim S, Chuah K, Rajaram R, Stanley K, Shahrani S, Chan W . Epidemiological trends of gastrointestinal and liver diseases in Malaysia: A single-center observational study. J Gastroenterol Hepatol. 2022; 37(9):1732-1740. DOI: 10.1111/jgh.15905. View

Standing H, Jarvis H, Orr J, Exley C, Hudson M, Kaner E . GPs' experiences and perceptions of early detection of liver disease: a qualitative study in primary care. Br J Gen Pract. 2018; 68(676):e743-e749. PMC: 6193778. DOI: 10.3399/bjgp18X699377. View

10.

Eslam M, Newsome P, Sarin S, Anstee Q, Targher G, Romero-Gomez M . A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020; 73(1):202-209. DOI: 10.1016/j.jhep.2020.03.039. View

11.

Matthias A, Fernandopulle A, Seneviratne S . Survey on knowledge of non-alcoholic fatty liver disease (NAFLD) among doctors in Sri Lanka: a multicenter study. BMC Res Notes. 2018; 11(1):556. PMC: 6076419. DOI: 10.1186/s13104-018-3673-2. View

12.

Lavekar A, Deshpande A, Raje D . Comparison of knowledge and awareness between consultant physicians and resident doctors about non-alcoholic fatty liver disease. Clin Exp Hepatol. 2021; 6(4):374-383. PMC: 7816641. DOI: 10.5114/ceh.2020.102152. View

13.

Malik A, Cheah P, Hilmi I, Chan S, Goh K . Non-alcoholic fatty liver disease in Malaysia: a demographic, anthropometric, metabolic and histological study. J Dig Dis. 2007; 8(1):58-64. DOI: 10.1111/j.1443-9573.2007.00286.x. View

14.

Sanyal A, Chalasani N, Kowdley K, McCullough A, Diehl A, Bass N . Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010; 362(18):1675-85. PMC: 2928471. DOI: 10.1056/NEJMoa0907929. View

15.

Wah Kheong C, Mustapha N, Mahadeva S . A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2017; 15(12):1940-1949.e8. DOI: 10.1016/j.cgh.2017.04.016. View

16.

Goh S, Ho E, Goh K . Prevalence and risk factors of non-alcoholic fatty liver disease in a multiracial suburban Asian population in Malaysia. Hepatol Int. 2015; 7(2):548-54. DOI: 10.1007/s12072-012-9359-2. View

17.

Kwok R, Choi K, Wong G, Zhang Y, Chan H, Luk A . Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut. 2015; 65(8):1359-68. DOI: 10.1136/gutjnl-2015-309265. View

18.

Chan W, Tan A, Vethakkan S, Tah P, Vijayananthan A, Goh K . Non-alcoholic fatty liver disease in diabetics--prevalence and predictive factors in a multiracial hospital clinic population in Malaysia. J Gastroenterol Hepatol. 2013; 28(8):1375-83. DOI: 10.1111/jgh.12204. View

19.

Said A, Gagovic V, Malecki K, Givens M, Nieto F . Primary care practitioners survey of non-alcoholic fatty liver disease. Ann Hepatol. 2013; 12(5):758-65. View

20.

Aithal G, Thomas J, Kaye P, Lawson A, Ryder S, Spendlove I . Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008; 135(4):1176-84. DOI: 10.1053/j.gastro.2008.06.047. View